Rigontec Overview

  • Founded
  • 2014
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $551M
Latest Deal Amount

Rigontec General Information

Description

Developer of RNA-based immunotherapeutics for cancer and viral diseases intended to harness one of the most essential pathways in the innate immune system. The company's RNA-based immunotherapeutics offers proprietary retinoic acid inducible gene I (RIG-I) activators for the treatment of cancer and is designed to initiate specific activation of multiple RIG-I pathways to kill tumor cells and to enable long-term immunity against the cancer associated with the tumor, enabling healthcare providers to generate effective therapies.

Contact Information

Website
www.rigontec.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Merck & Co.
Primary Office
  • Izb, Am Klopferspitz 19
  • Planegg/Martinsried
  • 82152 Munich
  • Germany
+49 089 000000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Rigontec Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 26-Oct-2017 $551M 000.00 00000 Completed Generating Revenue
2. Early Stage VC (Series A) 06-Sep-2016 000.00 000.00 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Rigontec’s complete valuation and funding history, request access »

Rigontec Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of RNA-based immunotherapeutics for cancer and viral diseases intended to harness one of the most essential pa
Biotechnology
Munich, Germany
000.00
0000 0000-00-00
000000&0 000.00

000000

aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cill
0000000000000
Utrecht, Netherlands
00 As of 0000
00.000
000000000000 00.000

0000000

eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud e
0000 000000000
Philadelphia, PA
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Rigontec Competitors (38)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gadeta Venture Capital-Backed Utrecht, Netherlands 00 00.000 000000000000 00.000
0000000 0000000000 Venture Capital-Backed Philadelphia, PA 00 00000 00000000000 00000
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
000000000000 Venture Capital-Backed Seattle, WA 00 000.00 00000000000 000.00
000000000 00000000 Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
You’re viewing 5 of 38 competitors. Get the full list »

Rigontec Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Boehringer Ingelheim Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
FORBION Venture Capital Minority 000 0000 000000 0
German Accelerator Accelerator/Incubator 000 0000 000000 0
High-Tech Gründerfonds Venture Capital Minority 000 0000 000000 0
MP Healthcare Venture Management Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial